Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

An artificial-intelligence algorithm that discovers its own way to learn achieves state-of-the-art performance, including on some tasks it had never encountered before. Joel Lehman is at Lila Sciences ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

“It is confusing. It’s exciting, and in a world of GPS and constant signage, you always know where you are, where you’re going," said Taylor Cooley, owner of Cool Patch Pumpkins. The owner of a giant ...

Copyright 2025 The Associated Press. All Rights Reserved. Copyright 2025 The Associated Press. All Rights Reserved. For nearly a quarter century, Cool Patch Pumpkins ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

A scene from The Maze Runner showing Dylan O’Brien as Thomas, caught in a moment of shock and realization while trapped inside the mysterious maze. Image via 20th Century Fox Feel free to connect with ...